NewAmsterdam Pharma (NAMSW) Competitors $13.78 -0.70 (-4.83%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMSW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. NewAmsterdam Pharma vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene 180 Life Sciences (NASDAQ:ATNFW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Is ATNFW or NAMSW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A NewAmsterdam Pharma N/A N/A N/A Does the media favor ATNFW or NAMSW? In the previous week, NewAmsterdam Pharma had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 0 mentions for 180 Life Sciences. NewAmsterdam Pharma's average media sentiment score of 1.26 beat 180 Life Sciences' score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral NewAmsterdam Pharma Positive Which has stronger earnings and valuation, ATNFW or NAMSW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ANewAmsterdam Pharma$64.01MN/AN/AN/AN/A SummaryNewAmsterdam Pharma beats 180 Life Sciences on 3 of the 3 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMSW vs. The Competition Export to ExcelMetricNewAmsterdam PharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$153.68M$5.84B$10.14BDividend YieldN/A3.78%5.68%4.60%P/E RatioN/A41.0875.4125.98Price / SalesN/A4,942.17515.95180.52Price / CashN/A13.1937.5660.44Price / BookN/A103.7512.156.29Net IncomeN/A-$90.99M$3.29B$271.07M7 Day Performance-7.97%2.86%0.74%3.87%1 Month Performance4.55%21.20%5.00%5.49%1 Year PerformanceN/A526.77%62.55%25.86% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSWNewAmsterdam PharmaN/A$14.26-1.5%N/A+112.5%$0.00$64.01M0.0029Positive NewsATNFW180 Life SciencesN/A$0.22+8.3%N/A+1,189.8%$0.00N/A0.007Gap UpSXTPW60 Degrees PharmaceuticalsN/A$0.07-28.3%N/AN/A$0.00$641.41K0.002DRTSWAlpha Tau MedicalN/A$0.29+0.9%N/AN/A$0.00N/A0.0080Gap DownAPLMWApollomicsN/A$0.01+29.9%N/A+68.9%$0.00N/A0.0059Short Interest ↓Gap UpHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.02-16.8%N/A-84.4%$0.00N/A0.008Short Interest ↑Gap DownCDIOWCardio DiagnosticsN/A$0.02-1.1%N/A-39.6%$0.00$19.51K0.007Positive NewsShort Interest ↓CELUWCelularityN/A$0.04-31.7%N/A+173.2%$0.00$44.59M0.00220High Trading VolumeCEROWCERo TherapeuticsN/A$0.02-1.6%N/A+40.0%$0.00N/A0.008Positive NewsGap DownCINGWCingulateN/A$0.06flatN/A-24.4%$0.00N/A0.0020Gap UpCLNNWCleneN/A$0.03-13.7%N/A-48.2%$0.00$286K0.00100Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 60 Degrees Pharmaceuticals Alternatives Alpha Tau Medical Alternatives Apollomics Alternatives BriaCell Therapeutics Alternatives Cardio Diagnostics Alternatives Celularity Alternatives CERo Therapeutics Alternatives Cingulate Alternatives Clene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMSW) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMSW Stock Alerts